Sagar Patel presents the REVELUTION trial comparing leuprolide versus relugolix effects on coronary plaque progression in 94 men with non-metastatic prostate cancer receiving pelvic radiotherapy.

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...

Immunohistochemical Expression of Nectin-4 and Potential Implications for Enfortumab Vedotin Therapy in Germ Cell Tumors of the Testis: A Preliminary Study - Beyond the Abstract ...

ESMO 2025, PSMA-positive metastatic hormone-sensitive prostate cancer, [177Lu]Lu-PSMA-617, VISION trial, PSMAfore trial, PSMAddition trial, 68Ga-PSMA-11 PET/CT.

The Role of Early, Multi-Modal Genomic Testing in Prostate Cancer ManagementSent on 12 January 2026 Prostate Cancer DailySent on 12 January 2026 Prostate Cancer DailySent on 09 January 2026 Why Timing ...

Inherited Defects of piRNA Biogenesis Cause Transposon De-Repression, Impaired Spermatogenesis, and Human Male Infertility - Beyond the Abstract ...

Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

ASCO 2025 overall survival analysis of enzalutamide plus androgen-deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC), ARCHES study.

SUO 2025 BRCA-mutated metastatic castration-resistant prostate cancer, results from the TRITON3 study, rucaparib in BRCA-mutated mCRPC.

ESMO 2024, High and Intermediate Risk Non Muscle Invasive Bladder Cancer (HMR-NMIBC), Trifunctional Anti-EpCAM/CD3 bsAb Catumaxomab Intravesically, catumaxomab (CAT), EpCAM+ tumor cells.